Revvity (RVTY) Research | Aerarium Research

Forward Estimates

EPS Estimates

Current Qtr

$1.22

$1.19$1.28

vs $1.18+3.4%

12 analysts

Next Qtr

$1.31

$1.29$1.33

vs $1.18+11.1%

12 analysts

Current Yr

$5.25

$5.21$5.29

vs $5.06+3.7%

12 analysts

Next Yr

$5.82

$5.65$6.09

vs $5.25+11.0%

12 analysts

Revenue Estimates

Current Qtr

$705.89M

$696.00M$727.20M

vs $720.28M-2.0%

11 analysts

Next Qtr

$692.04M

$679.00M$726.30M

vs $698.95M-1.0%

11 analysts

Current Yr

$2.85B

$2.82B$2.96B

vs $2.86B-0.4%

11 analysts

Next Yr

$2.99B

$2.96B$3.11B

vs $2.85B+5.2%

11 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for RVTY on EDGAR.

RVTY filing events and research context
Filed	Item	Context
Feb 24, 2026	business	Revvity provides health science solutions across two primary segments: Life Sciences and Diagnostics. The Life Sciences segment supports drug discovery and development for pharmaceutical and biotech clients through a portfolio of reagents (BioLegend antibodies, HTRF, AlphaLISA), instruments (Opera Phenix high-content screening, IVIS in vivo imaging), and informatics software (Signals Research, ChemDraw). The company also leverages the Pin-point CRISPR-based base editing platform and CHOSOURCE expression system to accelerate therapeutic development. The Diagnostics segment focuses on reproductive health and immunodiagnostics, offering prenatal screening via DELFIA Xpress, newborn metabolic screening through NeoLSD, and infectious disease testing such as T-SPOT.TB. Revvity is currently prioritizing the integration of artificial intelligence to enhance product differentiation and operational efficiency, while pursuing growth through strategic acquisitions and R&D. The company markets its products in over 160 countries using a combination of a direct sales force and third-party distributors. While most raw materials are readily available, the company faces operational risk from a limited or single-source supply for certain critical components.
Feb 24, 2026	mda	Fiscal year 2025 revenue increased 4% to $2,856.1 million, driven by a 5% rise in Diagnostics—specifically within Immunodiagnostics and Reproductive Health—and a 2% increase in Life Sciences, led by the Software business. Consolidated gross margin declined 104 basis points to 54.8%, pressured by unfavorable foreign exchange rates, product mix shifts, and approximately $20 million in net tariff impacts on European-manufactured products sold in the U.S. Operating margins decreased 10 basis points, partially offset by productivity initiatives and a $55.9 million restructuring charge associated with facility consolidations and a 5% workforce reduction. Research and development expenses rose 10% to $215.8 million to support new product development. Net cash from operating activities fell to $589.0 million, impacted by the timing of collections in China. The company maintains liquidity via a new $1.5 billion revolving credit facility and $919.9 million in cash, though it faces a €500 million note maturity in July 2026. A notable financial risk is the Life Sciences Solutions reporting unit, where fair value exceeded carrying value by only 10% to 20% during November 2025 testing, increasing the potential for future goodwill impairment.
Feb 24, 2026	risk_factors	Revvity faces significant financial headwinds from increased tariffs, which added $25 million to the cost of revenue, primarily affecting European products sold in the U.S. market. The company is highly exposed to foreign exchange volatility, as 60% of its business is conducted outside the U.S., with primary exposure to the Chinese Renminbi, Euro, British Pound, and Singapore Dollar. In the Diagnostics segment, changes to China's diagnostic testing policies have negatively impacted product mix and operating margins. A critical valuation risk exists within the Life Sciences Solutions reporting unit, where $4.5 billion in goodwill has a fair value exceeding its carrying value by only 10% to 20%, increasing the potential for future impairment charges. Operational risks are being managed through workforce reductions affecting 5% of staff and facility consolidations to streamline operations. Liquidity considerations include the upcoming maturity of €500 million in Senior Unsecured Notes in July 2026. Furthermore, the company faces regulatory and tax uncertainty stemming from ongoing audits in Germany and Singapore.

Filed

Item

Context

Feb 24, 2026

business

Revvity provides health science solutions across two primary segments: Life Sciences and Diagnostics. The Life Sciences segment supports drug discovery and development for pharmaceutical and biotech clients through a portfolio of reagents (BioLegend antibodies, HTRF, AlphaLISA), instruments (Opera Phenix high-content screening, IVIS in vivo imaging), and informatics software (Signals Research, ChemDraw). The company also leverages the Pin-point CRISPR-based base editing platform and CHOSOURCE expression system to accelerate therapeutic development. The Diagnostics segment focuses on reproductive health and immunodiagnostics, offering prenatal screening via DELFIA Xpress, newborn metabolic screening through NeoLSD, and infectious disease testing such as T-SPOT.TB. Revvity is currently prioritizing the integration of artificial intelligence to enhance product differentiation and operational efficiency, while pursuing growth through strategic acquisitions and R&D. The company markets its products in over 160 countries using a combination of a direct sales force and third-party distributors. While most raw materials are readily available, the company faces operational risk from a limited or single-source supply for certain critical components.

Feb 24, 2026

mda

Fiscal year 2025 revenue increased 4% to $2,856.1 million, driven by a 5% rise in Diagnostics—specifically within Immunodiagnostics and Reproductive Health—and a 2% increase in Life Sciences, led by the Software business. Consolidated gross margin declined 104 basis points to 54.8%, pressured by unfavorable foreign exchange rates, product mix shifts, and approximately $20 million in net tariff impacts on European-manufactured products sold in the U.S. Operating margins decreased 10 basis points, partially offset by productivity initiatives and a $55.9 million restructuring charge associated with facility consolidations and a 5% workforce reduction. Research and development expenses rose 10% to $215.8 million to support new product development. Net cash from operating activities fell to $589.0 million, impacted by the timing of collections in China. The company maintains liquidity via a new $1.5 billion revolving credit facility and $919.9 million in cash, though it faces a €500 million note maturity in July 2026. A notable financial risk is the Life Sciences Solutions reporting unit, where fair value exceeded carrying value by only 10% to 20% during November 2025 testing, increasing the potential for future goodwill impairment.

Feb 24, 2026

risk_factors

Revvity faces significant financial headwinds from increased tariffs, which added $25 million to the cost of revenue, primarily affecting European products sold in the U.S. market. The company is highly exposed to foreign exchange volatility, as 60% of its business is conducted outside the U.S., with primary exposure to the Chinese Renminbi, Euro, British Pound, and Singapore Dollar. In the Diagnostics segment, changes to China's diagnostic testing policies have negatively impacted product mix and operating margins. A critical valuation risk exists within the Life Sciences Solutions reporting unit, where $4.5 billion in goodwill has a fair value exceeding its carrying value by only 10% to 20%, increasing the potential for future impairment charges. Operational risks are being managed through workforce reductions affecting 5% of staff and facility consolidations to streamline operations. Liquidity considerations include the upcoming maturity of €500 million in Senior Unsecured Notes in July 2026. Furthermore, the company faces regulatory and tax uncertainty stemming from ongoing audits in Germany and Singapore.

Forward Estimates

RVTY filing events and research context

Keep researching RVTY

Related tickers

Related explainers

Forward Estimates